AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30136619 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (5 capsules of fish-oil-derived omega-3, each 1 g containing 180 mg eicosapentaenoic acid and 120 mg docosahexanoic acid)
Number of subjects: 54
Study 30136619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 30136619 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation
Number of subjects: 54
Study 26359113 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid vaccination
Number of subjects: 24
Study 26359113 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) injection
Number of subjects: 24
Study 24774260 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized glucose control with insulin (target glucose, 80-120 mg/dL)
Number of subjects: 104
Study 24774260 — intervention group
Group type: COMPARATOR
Intervention: Conventional control (target glucose, <180 mg/dL)
Number of subjects: 104
Study 22660798 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 55
Study 22660798 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) and TNF-α inhibitors
Number of subjects: 55
Study 20194522 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0
Study 20194522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18612266 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive words (PW, N=248)
Number of subjects: 614
Study 18612266 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially negative words (NW1, N=241)
Number of subjects: 614
Study 18612266 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally negative words (NW2, N=247)
Number of subjects: 614
Study 18612266 — intervention group
Group type: COMPARATOR
Intervention: No words (NW, N=35)
Number of subjects: 614
Study 16470437 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg before operation and twice thereafter at 8-hour intervals)
Number of subjects: 39
Study 16470437 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving tranexamic acid)
Number of subjects: 39
Study 12433712 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of serum glucose
Number of subjects: 10786
Study 12433712 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of insulin
Number of subjects: 10786
Study 12433712 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of IGF-I
Number of subjects: 10786
Study 12433712 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of IGFBP-3
Number of subjects: 10786
Study 10651393 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (100 mg once daily for 3 days, then 20 mg once daily)
Number of subjects: 0
Study 10651393 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 0
Study 8944081 — intervention group
Group type: COMPARATOR
Intervention: SPf66 vaccine
Number of subjects: 630
Study 8944081 — intervention group
Group type: COMPARATOR
Intervention: Inactivated polio vaccine (IPV)
Number of subjects: 630
Study 1759005 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 0.3 mg, tid + Beclomethasone dipropionate 0.2 mg, tid
Number of subjects: 10
Study 1759005 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 0.3 mg, tid + Placebo
Number of subjects: 10
Study 6130076 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 40 mg
Number of subjects: 24
Study 6130076 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg
Number of subjects: 24
Study 6130076 — intervention group
Group type: COMPARATOR
Intervention: Methaqualone 300 mg
Number of subjects: 24
Study 6130076 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 20 mg
Number of subjects: 24
Study 6130076 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 24
Study 6130076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31215299 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) treatment (4 cycles of 5-minute ischemia followed by 5-minute reperfusion)
Number of subjects: 36
Study 31215299 — intervention group
Group type: COMPARATOR
Intervention: Sham-device treatment
Number of subjects: 36
Study 28764777 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% betamethasone gel
Number of subjects: 120
Study 28764777 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine jelly
Number of subjects: 120
Study 28764777 — intervention group
Group type: COMPARATOR
Intervention: Unlubricated endotracheal tube (Control)
Number of subjects: 120
Study 27647062 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-Based Intervention (WI)
Number of subjects: 1488
Study 27647062 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1488
Study 25797743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg po bid for 14 days
Number of subjects: 13
Study 25797743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib 2 mg po daily for 14 days
Number of subjects: 13
Study 25797743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib therapy
Number of subjects: 13
Study 25797743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib and trametinib therapy
Number of subjects: 13
Study 22490614 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine formulae
Number of subjects: 327
Study 22490614 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine formulae (specifically Jing Fan Bai Du san)
Number of subjects: 327
Study 22490614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 20968018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined photon‐neutron radiotherapy (CPNT)
Number of subjects: 33
Study 20968018 — intervention group
Group type: COMPARATOR
Intervention: Control group (photon therapy)
Number of subjects: 33
Study 17875601 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mT m(‐1)r.m.s. EMF exposure
Number of subjects: 40
Study 17875601 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mT m(‐1)r.m.s. EMF exposure
Number of subjects: 40
Study 17875601 — intervention group
Group type: COMPARATOR
Intervention: 0 mT m(‐1)r.m.s. (non-exposed sessions)
Number of subjects: 40
Study 16043964 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (3 g/day)
Number of subjects: 83
Study 16043964 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valacyclovir (8 g/day)
Number of subjects: 83
Study 16043964 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control group)
Number of subjects: 83
Study 12072104 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccination with levamisole (80 mg after each hemodialysis session for 4 months)
Number of subjects: 96
Study 12072104 — intervention group
Group type: EXPERIMENTAL
Intervention: Second HBV vaccination program with levamisole
Number of subjects: 96
Study 12072104 — intervention group
Group type: COMPARATOR
Intervention: Second HBV vaccination program without levamisole
Number of subjects: 96
Study 12072104 — intervention group
Group type: COMPARATOR
Intervention: HBV vaccination without levamisole
Number of subjects: 96
Study 10084038 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular injection of 1.5 ml (40 mg/ml) methylprednisolone acetate and 1.5 ml (20 mg/ml) lignocaine (MP group)
Number of subjects: 20
Study 10084038 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride and 1.5 ml (20 mg/ml) lignocaine (non‐MP group)
Number of subjects: 20
Study 8571928 — intervention group
Group type: EXPERIMENTAL
Intervention: Press needle technique (PN)
Number of subjects: 31
Study 8571928 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 31
Study 8571928 — intervention group
Group type: EXPERIMENTAL
Intervention: In-situ technique (IS)
Number of subjects: 31
Study 2187525 — intervention group
Group type: COMPARATOR
Intervention: Intravenous treosulfan
Number of subjects: 135
Study 2187525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous treosulfan plus cisplatinum
Number of subjects: 135
Study 6142462 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.5 to 1 mg 3-times daily)
Number of subjects: 30
Study 6142462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6142462 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 30
Study 30370983 — intervention group
Group type: EXPERIMENTAL
Intervention: Active deep rTMS (1 Hz at 120% of individual motor threshold)
Number of subjects: 16
Study 30370983 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 16
Study 29083258 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 2 mg once daily for 24 weeks
Number of subjects: 255
Study 29083258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 26791921 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose caffeine (loading 20 mg/kg and maintenance of 15 mg/(kg·d) after 24 h)
Number of subjects: 164
Study 26791921 — intervention group
Group type: COMPARATOR
Intervention: Low-dose caffeine (loading 20 mg/kg and maintenance of 5 mg/(kg·d) after 24 h)
Number of subjects: 164
Study 24902983 — intervention group
Group type: EXPERIMENTAL
Intervention: USL255 (200 mg/day)
Number of subjects: 249
Study 24902983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 21960311 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPIRI/CAPOX plus cetuximab
Number of subjects: 146
Study 19649708 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 20238281 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture (group 1, verum open, N = 4)
Number of subjects: 11
Study 20238281 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture (group 2, verum blind, N = 3)
Number of subjects: 11
Study 20238281 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 3, placebo blind, N = 4)
Number of subjects: 11
Study 20238281 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including both verum and placebo)
Number of subjects: 11
Study 16218261 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg
Number of subjects: 171
Study 16218261 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron/Dolasetron
Number of subjects: 171
Study 12398958 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 238
Study 12398958 — intervention group
Group type: COMPARATOR
Intervention: Uncoated metal stent (UMS)
Number of subjects: 238
Study 9973769 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g vitamin C
Number of subjects: 17
Study 9973769 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for vitamin C trial)
Number of subjects: 17
Study 9973769 — intervention group
Group type: EXPERIMENTAL
Intervention: 105 g carbohydrate
Number of subjects: 17
Study 9973769 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for carbohydrate trial)
Number of subjects: 17
Study 7923512 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (100 micrograms)
Number of subjects: 100
Study 7923512 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (100 micrograms)
Number of subjects: 100
Study 7923512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-over patients (41 patients)
Number of subjects: 100
Study 7923512 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 100
Study 7923512 — intervention group
Group type: COMPARATOR
Intervention: Epidural fentanyl
Number of subjects: 100
Study 3262637 — intervention group
Group type: EXPERIMENTAL
Intervention: Active device (electrical stimulation applied to the tongue and hard palate)
Number of subjects: 29
Study 3262637 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 29
Study 3262637 — intervention group
Group type: EXPERIMENTAL
Intervention: Active device
Number of subjects: 29
Study 27359164 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Parent Training (BPT)
Number of subjects: 551
Study 27359164 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Management Training, Oregon Model (PMTO)
Number of subjects: 551
Study 27359164 — intervention group
Group type: COMPARATOR
Intervention: Individual Social Skills Training (ISST)
Number of subjects: 551
Study 27058647 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 34
Study 27058647 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 34
Study 25362110 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg of aspirin
Number of subjects: 30
Study 25362110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22494121 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal indomethacin
Number of subjects: 602
Study 22494121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study 20719809 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone (200 mg, 3 times a day)
Number of subjects: 468
Study 20719809 — intervention group
Group type: COMPARATOR
Intervention: No luteal phase support
Number of subjects: 468
Study 18519268 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-combined hormone replacement therapy (ccHRT) with estradiol valerate/medroxyprogesterone acetate (E(2)V/MPA) at dosages of 1 mg + 2.5 mg (n = 69), 1 mg + 5 mg (n = 70), or 2 mg + 5 mg (n = 140) for 8.5 years.
Number of subjects: 279
Study 18519268 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-combined hormone replacement therapy (ccHRT) with estradiol valerate/medroxyprogesterone acetate (E(2)V/MPA)
Number of subjects: 279
Study 18519268 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discontinuation of ccHRT
Number of subjects: 279
Study 16170117 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 451
Study 16170117 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 451
Study 16170117 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 451
Study 12855348 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention involving sectioning of the tendon to the internal obturator muscle near its insertion at the trochanter
Number of subjects: 6
Study 12855348 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgical intervention)
Number of subjects: 6
Study 10491352 — intervention group
Group type: COMPARATOR
Intervention: BRS(Phe)
Number of subjects: 49
Study 10491352 — intervention group
Group type: COMPARATOR
Intervention: BRS(alphaLF)
Number of subjects: 49
Study 10491352 — intervention group
Group type: COMPARATOR
Intervention: BRS(alphaHF)
Number of subjects: 49
Study 10491352 — intervention group
Group type: COMPARATOR
Intervention: BRS(Seq)
Number of subjects: 49
Study 10491352 — intervention group
Group type: COMPARATOR
Intervention: BRS(Cbr)
Number of subjects: 49
Study 8559529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical PGE2 gel
Number of subjects: 118
Study 8559529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 1724669 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost infusion (0.5-0.2 ng/kg/min for 6 hours per day for 2 weeks)
Number of subjects: 102
Study 1724669 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion for 2 weeks
Number of subjects: 102
Study 6343462 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocortin butyl (FCB) 2 mg
Number of subjects: 306
Study 6343462 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocortin butyl (FCB) 4 mg
Number of subjects: 306
Study 6343462 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocortin butyl (FCB) 8 mg
Number of subjects: 306
Study 6343462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 30804399 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care intervention
Number of subjects: 12
Study 30804399 — intervention group
Group type: COMPARATOR
Intervention: Passive movement control
Number of subjects: 12
Study 30341154 — intervention group
Group type: EXPERIMENTAL
Intervention: FACE pACP (pediatric advance care planning survey, Respecting Choices interview, 5 Wishes directive)
Number of subjects: 105
Study 30341154 — intervention group
Group type: COMPARATOR
Intervention: Control (developmental history, safety tips, nutrition and exercise tips)
Number of subjects: 105
Study 26990694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus dosage determined by CYP3A5 genotype
Number of subjects: 236
Study 26990694 — intervention group
Group type: COMPARATOR
Intervention: Fixed dosage of tacrolimus
Number of subjects: 236
Study 24572452 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1‐α hydroxyvitamin D3)
Number of subjects: 94
Study 24572452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 22013959 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel injection (2 ml, 3.5% micronised hyaluronic acid) using the fan technique
Number of subjects: 60
Study 22013959 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel injection (2 ml, 3.5% micronised hyaluronic acid) using the multiple puncture technique
Number of subjects: 60
Study 20846688 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guérin with recommended daily allowance vitamins
Number of subjects: 670
Study 20846688 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guérin with megadose vitamins
Number of subjects: 670
Study 20846688 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guérin/interferon α‐2b with recommended daily allowance vitamins
Number of subjects: 670
Study 20846688 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guérin/interferon α‐2b with megadose vitamins
Number of subjects: 670
Study 20846688 — intervention group
Group type: COMPARATOR
Intervention: Bacillus Calmette‐Guérin alone
Number of subjects: 670
Study 20846688 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guérin plus interferon α‐2b
Number of subjects: 670
Study 17604562 — intervention group
Group type: EXPERIMENTAL
Intervention: Quyu Xiaoban capsules (QYXB) plus aspirin (300 mg loading dose, 100 mg maintenance dose)
Number of subjects: 90
Study 17604562 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (300 mg loading dose, 100 mg maintenance dose) plus baseline therapy
Number of subjects: 90
Study 16220098 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraminidase inhibitors
Number of subjects: 0
Study 16220098 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (Control)
Number of subjects: 0
Study 11215574 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (mean dose 28.78 mg/day)
Number of subjects: 53
Study 11215574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 11215574 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 53
Study 9623930 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment and sterilization guidelines introduced; seminars held at health centres; assessed 4 months post-intervention.
Number of subjects: 66
Study 8075732 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated telephone reminder or recall message
Number of subjects: 8002
Study 8075732 — intervention group
Group type: COMPARATOR
Intervention: No message (control group)
Number of subjects: 8002
Study 8075732 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated telephone message received
Number of subjects: 8002
Study 2811066 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium acetate (50 mEq Ca++)
Number of subjects: 6
Study 2811066 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (50 mEq Ca++)
Number of subjects: 6
Study 803895 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate mixture of fructose, glucose and xylitol (2:1:1)
Number of subjects: 0
Study 803895 — intervention group
Group type: COMPARATOR
Intervention: Fructose
Number of subjects: 0
Study 803895 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 0
Study 803895 — intervention group
Group type: COMPARATOR
Intervention: Xylitol
Number of subjects: 0
Study 30816851 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous (weight and diet tracking with weekly lessons, action plans, and feedback)
Number of subjects: 105
Study 30816851 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential (weight tracking for 4 weeks, then added diet tracking with the same behavioral components)
Number of subjects: 105
Study 30816851 — intervention group
Group type: EXPERIMENTAL
Intervention: App-Only (only diet tracking)
Number of subjects: 105
Study 28432876 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachio-supplemented diet (PD, 50% carbohydrates, 33% fat, including 57 g/d of pistachios daily)
Number of subjects: 39
Study 28432876 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachio-supplemented diet (PD)
Number of subjects: 39
Study 25474490 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography for diagnosis of OSAS
Number of subjects: 453
Study 23673889 — intervention group
Group type: EXPERIMENTAL
Intervention: SISTA South Africa intervention
Number of subjects: 342
Study 23673889 — intervention group
Group type: COMPARATOR
Intervention: General health comparison
Number of subjects: 342
Study 21843366 — intervention group
Group type: EXPERIMENTAL
Intervention: REFRESH Program (intervention group)
Number of subjects: 900
Study 21843366 — intervention group
Group type: COMPARATOR
Intervention: No intervention materials (control group)
Number of subjects: 900
Study 19536165 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily replacement of one meal with a low-calorie diet formula
Number of subjects: 62
Study 19536165 — intervention group
Group type: COMPARATOR
Intervention: Dieting alone for another 6 months
Number of subjects: 62
Study 17352632 — intervention group
Group type: EXPERIMENTAL
Intervention: 904-nm low-level laser irradiation (10 mW/cm² power density, 4 mW output power, 0.4 cm² spot size, 0.48 J dose per session, 120-sec treatment time)
Number of subjects: 52
Study 17352632 — intervention group
Group type: COMPARATOR
Intervention: Placebo-laser therapy
Number of subjects: 52
Study 17352632 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Group I and Group II
Number of subjects: 52